Mikael Thune

Title: Mikael Thune: Innovator in Pharmaceutical Formulations

Introduction

Mikael Thune is a notable inventor based in Mölndal, Sweden. He has made significant contributions to the field of pharmaceutical formulations, particularly in modified release compositions. With a total of 3 patents to his name, Thune's work is recognized for its potential impact on treating cardiovascular disorders.

Latest Patents

Mikael Thune's latest patents focus on modified release pharmaceutical formulations. One of his patents describes a modified release pharmaceutical composition that includes a compound of formula (I), where R represents Calkyl substituted by one or more fluoro substituents. The formulation is designed to treat cardiovascular disorders and may contain specific ingredients such as iota-carrageenan and a neutral gelling polymer when the compound is in the form of a salt. Another patent reiterates similar components and applications, emphasizing the innovative approach to drug delivery in cardiovascular treatment.

Career Highlights

Thune is currently employed at AstraZeneca AB, a leading global biopharmaceutical company. His role involves research and development in the pharmaceutical sector, where he applies his expertise in creating effective drug formulations. His contributions have been instrumental in advancing therapeutic options for patients.

Collaborations

Mikael Thune has collaborated with notable colleagues, including Anders Magnusson and Per Johan Lundberg. These partnerships have fostered a collaborative environment that enhances innovation and research in pharmaceutical sciences.

Conclusion

Mikael Thune's work in modified release pharmaceutical formulations showcases his dedication to improving healthcare solutions. His patents reflect a commitment to innovation in the treatment of cardiovascular disorders, making him a valuable contributor to the field of pharmaceuticals.